MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy
Clinical Trials
Related News

Sanofi Acquires Dren Bio's Novel B-Cell Depleter for $600 Million, Expanding Immunology Pipeline

• Sanofi has agreed to acquire Dren Bio's DR-0201, a first-in-class bispecific myeloid cell engager that induces deep B-cell depletion, for an upfront payment of $600 million. • DR-0201 works by targeting CD20 and engaging tissue-resident myeloid cells, potentially resetting the immune system in patients with refractory B-cell mediated autoimmune diseases like lupus. • The acquisition strengthens Sanofi's immunology portfolio and includes potential future payments of $1.3 billion upon achievement of development and launch milestones, with transaction expected to close in Q2 2025.

Breakthrough in Infertility Treatment: rhFSH-CTP Shows Promise in Clinical Trials

A novel long-acting recombinant human follicle-stimulating hormone, rhFSH-CTP, has demonstrated significant potential in improving infertility treatment outcomes. Clinical trials reveal that rhFSH-CTP can reduce the number of required injections, enhance patient compliance, and maintain therapeutic efficacy, marking a significant advancement in assisted reproductive technologies.

Short-Term Hormone Therapy for Menopause Shows No Long-Term Cognitive Harm

• A new study reveals that short-term hormone replacement therapy (HRT) for menopausal symptoms does not negatively impact cognitive function in women over the long term. • The research followed women for 10 years after they completed a 4-year course of HRT and found no significant difference in cognitive performance compared to those who received a placebo. • While HRT does not appear to harm the brain, the study also indicates that it should not be considered a method for improving neurological health during aging. • Researchers emphasize the need for further investigation into the long-term health outcomes of menopausal hormone therapy, including its potential effects on mood and Alzheimer's disease biomarkers.

Daré Bioscience Advances Women's Health Portfolio with Funding and Clinical Progress

• Daré Bioscience is progressing its hormone-free contraceptive, Ovaprene, in a Phase 3 efficacy study, boosted by a foundation grant to expand clinical sites. • Sildenafil Cream 3.6% for female sexual arousal disorder is advancing towards Phase 3 after constructive FDA discussions on trial design and endpoints. • DARE-HPV, a novel treatment for HPV-related cervical diseases, is set for a Phase 2 trial, supported by a $10 million ARPA-H award. • Activities are underway for Phase 2 and Phase 1 studies of DARE-VVA1 and DARE-PTB1, respectively, targeting dyspareunia and preterm birth prevention.

Synbiotic Supplementation to Prevent Preterm Birth: A Multi-Center Trial

• A multi-center, randomized, placebo-controlled trial is underway to investigate the efficacy of synbiotic supplementation in preventing spontaneous preterm birth (sPTB). • Pregnant women at risk for sPTB between 80/7 and 106/7 weeks of gestation will receive either a synbiotic containing eight Lactobacillus strains or a placebo daily until delivery. • The primary outcome is gestational age at delivery, with secondary outcomes including PTB rates, PPROM rates, vaginal microbiome analysis, and neonatal outcomes. • The trial aims to recruit 402 participants across seven Belgian teaching hospitals over approximately 36 months to determine if synbiotics can prolong pregnancy and improve neonatal health.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy